Myriad Genetics, Inc. provided earnings guidance for the fiscal year 2022. For the year, the company expects revenue to be in the range of $670 million to $700 million and GAAP LPS to be in the range of $0.90 to $0.70.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
18.07 USD | -3.01% | -2.03% | -5.25% |
Mar. 20 | Myriad Genetics Gets US Patent for SneakPeek Snap Device | MT |
Feb. 27 | Transcript : Myriad Genetics, Inc., Q4 2023 Earnings Call, Feb 27, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.25% | 1.69B | |
-1.09% | 12.72B | |
-12.53% | 7.5B | |
+0.45% | 5.48B | |
-1.37% | 4.61B | |
+3.82% | 4.47B | |
-52.68% | 3.28B | |
+11.34% | 2.71B | |
-19.05% | 2.02B | |
-11.07% | 1.74B |
- Stock Market
- Equities
- MYGN Stock
- News Myriad Genetics, Inc.
- Myriad Genetics, Inc. Provides Earnings Guidance for the Fiscal Year 2022